Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on TransMedics Group (TMDX – Research Report). The associated price target was raised to $146.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors, including anticipated developments and strategic positioning. Jennings highlights the potential for FDA approval to expand the label of OCS Liver, expected in the fall, which could significantly enhance the company’s market position and growth prospects.
Additionally, despite the current market competition and focus on quarterly results, Jennings remains optimistic about the company’s long-term potential. The recent increase in the stock price target to $146, based on future earnings estimates, further underscores his confidence in TransMedics Group’s ability to deliver value to shareholders.
In another report released on May 12, Canaccord Genuity also maintained a Buy rating on the stock with a $129.00 price target.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMDX in relation to earlier this year.